Details

Autor(en) / Beteiligte

• Flaherty, Keith T
• Robert, Caroline
• Hersey, Peter
• Nathan, Paul
• Garbe, Claus
• Milhem, Mohammed
• Demidov, Lev V
• Hassel, Jessica C
• Rutkowski, Piotr
• Mohr, Peter
• Dummer, Reinhard
• Trefzer, Uwe
• Larkin, James M.G
• Utikal, Jochen
• Dreno, Brigitte
• Nyakas, Marta
• Middleton, Mark R
• Becker, Jürgen C
• Casey, Michelle
• Sherman, Laurie J
• Wu, Frank S
• Ouellet, Daniele
• Martin, Anne-Marie
• Patel, Kiran
• Schadendorf, Dirk

Titel

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Ist Teil von

• The New England journal of medicine, 2012-07, Vol.367 (2), p.107-114

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2012

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Treatment with trametinib, a MEK inhibitor, resulted in significantly improved progression-free and overall survival, as compared with chemotherapy, in patients with advanced melanoma and activating BRAF mutations. About 160,000 new cases of melanoma are diagnosed and 48,000 melanoma-related deaths occur worldwide each year. 1 Among cancers in patients under 40 years of age, the incidence of melanoma is second only to that of breast cancer for women and leukemia for men. 2 Before 2010, no systemic therapy had been shown to improve overall survival among patients with metastatic melanoma, and only modest improvements were observed with interferon as an adjuvant drug. 3 Ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), and vemurafenib, a selective BRAF inhibitor, have both been shown to improve survival among patients with metastatic melanoma . . .